Long COVID — the constellation of symptoms persisting weeks or months after acute SARS-CoV-2 infection — leaves many people dealing with fatigue, cognitive impairment, loss of smell, and widespread pain long after the initial illness resolves. Emerging research points to sustained neuroinflammation, mast cell hyperactivation, and disrupted neural signaling as key drivers of these lingering complaints, which collectively affect quality of life in ways that few available treatments adequately address.
Palmitoylethanolamide (PEA), an endogenous fatty acid amide produced naturally in human tissue, has attracted growing clinical interest as a supportive intervention for post-viral illness. PEA modulates inflammation primarily by activating PPAR-α nuclear receptors and stabilizing mast cells, reducing pro-inflammatory signaling in both the peripheral and central nervous systems without engaging opioid receptors. A body of clinical research, much of it conducted specifically in long COVID patients, has begun to examine whether PEA supplementation can help address the neuroinflammatory underpinnings of these persistent post-viral symptoms.
Key Takeaways
- Long COVID’s neuroinflammatory underpinnings — persistent mast cell activation, cytokine dysregulation, and disrupted neural signaling — are mechanistically aligned with PEA’s known actions as a PPAR-α agonist and mast cell stabilizer.
- Clinical trials have found evidence supporting co-ultramicronized PEA with luteolin for COVID-related olfactory dysfunction and associated cognitive impairment [6][2].
- Electrophysiological evidence suggests PEA-luteolin may help restore cortical GABAergic activity and plasticity disrupted by long COVID — an objective marker beyond symptom self-report [4].
- Formulation is critical: ultra-micronized and co-ultramicronized PEA with luteolin are the forms studied in this context; standard crystalline PEA may not replicate these outcomes.
- Current evidence is promising but still preliminary — larger, placebo-controlled trials with standardized long COVID endpoints are needed before definitive clinical recommendations can be made.
Long COVID as a Neuroinflammatory Condition
The pathophysiology of long COVID is multifaceted, but neuroinflammation has emerged as a central hypothesis. Following acute SARS-CoV-2 infection, the virus may trigger persistent immune activation, mast cell dysregulation, and ongoing cytokine release in neural tissue. This chronic low-grade inflammatory state is thought to impair neurotransmitter function, disrupt cortical plasticity, and interfere with olfactory processing — producing the cognitive and sensory symptoms many patients describe as uniquely debilitating.
Systematic reviews of long COVID interventions have highlighted the limited evidence base and the urgent need for targeted therapies [3]. Brain fog in particular has proven difficult to address, partly because its mechanisms overlap with those seen in other post-viral syndromes and partly because standard anti-inflammatory approaches do not easily cross the blood-brain barrier [8]. This gap has led researchers to explore agents that act on neuroinflammation at both peripheral and central levels — a profile that fits PEA’s known pharmacology.
How PEA Works: Mechanisms Relevant to Post-Viral Illness
PEA is synthesized on demand in cells throughout the body, including neurons and glial cells, in response to injury or inflammatory signals. Its primary actions are mediated through PPAR-α activation, which downregulates the transcription of pro-inflammatory genes, and through stabilization of mast cells — immune cells that, when hyperactivated, release histamine, cytokines, and other mediators that amplify neuroinflammation. PEA also interacts indirectly with the endocannabinoid system by inhibiting degradation of the endogenous cannabinoid anandamide, contributing to analgesic and neuroprotective effects.
Critically, PEA does not broadly suppress the immune system; it acts more as a modulator, helping to resolve excessive or dysregulated inflammatory responses. For long COVID, where the problem appears to be an inability to wind down the post-infectious inflammatory cascade rather than a deficiency of immune defense, this selective modulation is mechanistically appealing. PEA’s lipophilic nature also allows it to penetrate neural tissue, making it potentially relevant for symptoms driven by central nervous system inflammation. These properties have made it a focus of investigation for post-viral neurological symptoms [5].
PEA for Olfactory Dysfunction: Clinical Trial Evidence
Loss of smell (anosmia) or distorted smell (parosmia) after COVID-19 is one of the most studied applications of PEA in long COVID. The olfactory epithelium and olfactory bulb are particularly vulnerable to neuroinflammation, and sensory recovery can be slow or incomplete without targeted intervention. Researchers have examined whether PEA, combined with the flavonoid luteolin, can support olfactory recovery by reducing local neuroinflammation.
A blinded, controlled, multicenter randomized trial compared olfactory training alone, co-ultramicronized PEA with luteolin alone, and their combination in patients with COVID-19-related olfactory dysfunction [6]. The trial provided evidence that PEA-luteolin represents a viable intervention for this indication. A separate longitudinal study found that ultra-micronized PEA and luteolin were associated with improvements in both olfaction and memory in long COVID patients [2], suggesting that benefits may extend beyond the peripheral sensory organ to include central neural circuits involved in both smell processing and cognition.
The neuroinflammatory basis of chronic olfactory dysfunction in long COVID has also been reviewed specifically in the context of disease-modifying therapy, with PEA identified among the agents with a mechanistic rationale for further investigation [5]. The recurring theme across this work is that addressing neuroinflammation in the olfactory system — rather than relying solely on sensory retraining — may be necessary for meaningful, durable recovery.
Brain Fog, Cortical Plasticity, and GABAergic Signaling
Brain fog — characterized by difficulty concentrating, memory lapses, word-finding problems, and mental fatigue — is among the most debilitating long COVID symptoms and among the hardest to treat. Systematic review evidence acknowledges the scarcity of proven interventions and the need for strategies targeting its neurobiological basis [8].
One mechanistically significant study went beyond symptom self-report to examine cortical neurophysiology directly, finding that co-ultramicronized PEA with luteolin normalized GABAergic activity and restored markers of cortical plasticity in long COVID patients [4]. This matters because disrupted inhibitory neurotransmission and impaired cortical plasticity are proposed contributors to the cognitive symptoms of long COVID. Electrophysiological evidence of neural normalization, rather than just patient-reported improvement, strengthens the case that PEA-luteolin may act on underlying mechanisms rather than merely masking symptoms.
Real-World Evidence: Fatigue, Pain, and Broader Symptom Burden
Beyond olfaction and cognition, PEA has been evaluated for the broader symptom burden of long COVID in real-world clinical settings. A retrospective cohort study following patients treated with PEA in routine clinical practice found improvements across multiple symptom domains, including fatigue and pain, and the supplement was well tolerated across the observation period [1].
A separate retrospective analysis conducted by a network of general practitioners assessed co-ultramicronized PEA with luteolin across long COVID patients presenting in primary care settings [7]. Practitioners observed improvements in symptom clusters including fatigue, cognitive complaints, and musculoskeletal pain — consistent with the anti-neuroinflammatory mechanism proposed for PEA’s activity. Because these are retrospective, uncontrolled analyses, causation cannot be established; nonetheless, the pattern is consistent with findings from the controlled trial and mechanistic data and suggests that PEA may offer meaningful benefit across the long COVID symptom spectrum.
Formulation Matters: Ultra-Micronized and Co-Ultramicronized PEA
PEA is a solid at room temperature with limited natural bioavailability in standard crystalline form. The most clinically studied formulations are ultra-micronized (um-PEA) and co-ultramicronized (co-um-PEA), in which particle size is dramatically reduced to increase surface area and absorption. Co-ultramicronized formulations frequently combine PEA with luteolin — a naturally occurring flavonoid with its own anti-inflammatory and antioxidant activity — in a specific ratio designed to enhance bioavailability and extend the range of anti-inflammatory effects.
Nearly all of the long COVID clinical evidence reviewed here used um-PEA or co-um-PEA with luteolin, not standard PEA powder [6][2][4]. Consumers considering PEA for post-viral symptoms should look for products that explicitly state micronized or co-ultramicronized formulations. Dose ranges varied across studies; given the absence of universally established dosing, consulting a clinician familiar with PEA before starting supplementation is advisable.
🛒 Where to Buy Palmitoylethanolamide (PEA)
- Neurobiologix PEA (Palmitoylethanolamide) with Levagen+Lab-tested / studied
capsules, 400 mg PEA (as Levagen+) per capsule — Uses Gencor’s clinically studied Levagen+ branded ingredient; the same material used in human clinical trials; anchor recommendation - Nootropics Depot Palmitoylethanolamide Capsules
capsules, 600 mg per capsule — Community-trusted for third-party purity verification; higher per-capsule dose suited to those requiring 600–1200 mg daily - Double Wood Supplements Palmitoylethanolamide (PEA)
capsules, 400 mg per capsule — Budget-accessible with third-party testing certificates available; reliable entry-level option for new users - Liftmode Palmitoylethanolamide (PEA) Powder
powder, 400 mg per measured scoop — Certificate of analysis published per batch; powder form allows flexible dosing and is significantly cheaper per gram for long-term daily users
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
The available evidence on PEA for long COVID — while mechanistically grounded and supported by early trials and retrospective cohort data — is still preliminary; most studies are small, and large, rigorously controlled trials with standardized long COVID endpoints remain limited, meaning findings should be interpreted cautiously. PEA is a dietary supplement, not an FDA-approved treatment for any disease, and individuals with significant medical conditions, those taking immunosuppressants, anticoagulants, or chemotherapy, or those with serious post-COVID complications should consult a qualified healthcare provider before beginning any new supplement regimen.
Frequently Asked Questions
What is PEA and why is it being studied for long COVID?
PEA is an endogenous fatty acid amide produced in human tissue that modulates inflammation through PPAR-α activation and mast cell stabilization. Because long COVID appears to involve sustained neuroinflammation and immune dysregulation after the acute infection clears, PEA’s selective anti-inflammatory and neuroprotective profile makes it a mechanistically plausible candidate for supportive use [5].
Has PEA been tested in clinical trials for long COVID specifically?
Yes. A blinded multicenter randomized trial examined co-ultramicronized PEA with luteolin for COVID-related olfactory dysfunction [6], and a longitudinal study assessed its effects on olfaction and memory in long COVID patients [2]. Real-world retrospective cohort studies have also evaluated its use across broader long COVID symptom domains including fatigue and pain [1][7].
Can PEA help with brain fog after COVID?
Some evidence suggests it may. A study measuring cortical neurophysiology found that co-ultramicronized PEA with luteolin normalized GABAergic activity and markers of cortical plasticity in long COVID patients — changes that may underlie cognitive symptoms [4]. Systematic reviews note that proven brain fog interventions remain scarce, making this area an active priority for research [8].
Why is luteolin so often paired with PEA in long COVID research?
Luteolin is a flavonoid with complementary anti-inflammatory and antioxidant properties. In co-ultramicronized form, it is thought to amplify and broaden PEA’s anti-inflammatory effects, particularly in neural tissue, and may also improve PEA’s absorption. Virtually all long COVID clinical studies have used this combination rather than PEA alone [6][4].
How long might PEA supplementation need to be taken to notice effects in long COVID?
Study durations varied, and no consistent timeline has been established. The longitudinal study examining olfaction and memory tracked patients over several months [2], suggesting that meaningful changes may require sustained use. Individual responses likely depend on symptom severity, duration of illness, and the specific symptom domain targeted.
Are there any safety concerns with taking PEA for long COVID?
PEA has demonstrated a favorable tolerability profile across clinical trials and is not known to suppress the immune system broadly or engage opioid receptors. However, formal drug-interaction data are limited, and individuals taking immunosuppressants, anticoagulants, or undergoing chemotherapy should consult a physician before use. PEA is a dietary supplement, not an FDA-approved treatment for any disease.
References
- Raciti L et al. The Use of Palmitoylethanolamide in the Treatment of Long COVID: A Real-Life Retrospective Cohort Study. Medical sciences (Basel, Switzerland) (2022). PMID 35893119
- De Luca P et al. Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. Cells (2022). PMID 36010630
- Veronese N et al. Interventions for Improving Long COVID-19 Symptomatology: A Systematic Review. Viruses (2022). PMID 36146672
- Versace V et al. Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA(B)-ergic activity and cortical plasticity in long COVID-19 syndrome. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology (2023). PMID 36455453
- Di Stadio A et al. Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?. Life (Basel, Switzerland) (2023). PMID 36676175
- Di Stadio A et al. Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery (2023). PMID 37380908
- Pirro M et al. What Is the Role of Palmitoylethanolamide Co-Ultramicronized with Luteolin on the Symptomatology Reported by Patients Suffering from Long COVID? A Retrospective Analysis Performed by a Group of General Practitioners in a Real-Life Setting. Nutrients (2023). PMID 37686733
- Gorenshtein A et al. Intervention modalities for brain fog caused by long-COVID: systematic review of the literature. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2024). PMID 38695969
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
